Annual Report Forms for Postmarketing Requirements

Recommendation
12/13 November 2025
How to implement EU-GMP Chapter 8
The FDA published the final guidance on annual status reports and other submissions for postmarketing requirements (PMRs). The reports are intended to facilitate submissions by drug and biological product application holders of complete and accurate information on PMRs and postmarketing commitments (PMCs) in a consistent format. These forms are expected to result in improved accuracy and timeliness of FDA’s identification and review of those submissions containing information on PMRs and PMCs. The guidance covers
- the purpose of each form,
- when to use these forms,
- how to submit these forms.
The guidance also explains where applicants will be able to find the forms and instructions.
Background
Applicants are required to provide the agency with an annual report on the status of each PMR and PMC conducted to assess clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology of a human drug and biological product until FDA notifies the applicant, in writing, that the PMR or PMC has been fulfilled or that the PMR or PMC is no longer feasible or would no longer provide useful information.
This annual status report (ASR) on PMRs and PMCs must include the progress of the PMR or PMC or the reasons for failing to conduct the requirement or commitment. The specific milestone dates set forth as part of a PMR / PMC for conducting and completing a PMR / PMC include the following:
- Draft protocol submission date
- Final protocol submission date
- Study/clinical trial completion date
- Final report submission date
More information is available in FDA's Guidance for Industry Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989.
Related GMP News
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years
09.04.2025Q&A Document on QP Declaration updated
02.04.2025Switzerland: Update of the Technical Interpretation on the PQR